SCYNEXIS (NASDAQ:SCYX) Share Price Passes Above Fifty Day Moving Average – Time to Sell?

Posted by Brian Himes on Sep 10th, 2026

SCYNEXIS, Inc. (NASDAQ:SCYX – Get Free Report) crossed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $4.78 and traded as high as $5.35. SCYNEXIS shares last traded at $5.15, with a volume of 33,068 shares traded.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on SCYX shares. Wall Street Zen raised SCYNEXIS from a “strong sell” rating to a “hold” rating in a research report on Sunday, August 16th. Weiss Ratings upgraded SCYNEXIS from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, July 24th. Guggenheim reaffirmed a “buy” rating and set a $33.00 price target (up from $24.00) on shares of SCYNEXIS in a report on Thursday, August 13th. Finally, Brookline Capital Markets reissued a “buy” rating on shares of SCYNEXIS in a report on Friday, July 31st. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $33.00.

View Our Latest Stock Report on SCYX

SCYNEXIS Price Performance

The stock’s 50-day moving average price is $4.79 and its 200-day moving average price is $5.75. The company has a market cap of $46.77 million, a P/E ratio of -2.25 and a beta of 1.11.

SCYNEXIS (NASDAQ:SCYX – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported $0.63 earnings per share for the quarter, topping the consensus estimate of ($0.51) by $1.14. The business had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.08 million. SCYNEXIS had a negative net margin of 41.79% and a negative return on equity of 44.15%. As a group, analysts expect that SCYNEXIS, Inc. will post -1.6 EPS for the current fiscal year.

Institutional Investors Weigh In On SCYNEXIS

A number of institutional investors have recently made changes to their positions in SCYX. Empery Asset Management LP bought a new position in shares of SCYNEXIS during the second quarter worth about $514,656. Renaissance Technologies LLC raised its holdings in SCYNEXIS by 27.6% during the 1st quarter. Renaissance Technologies LLC now owns 224,640 shares of the company’s stock worth $206,000 after purchasing an additional 48,640 shares during the last quarter. Wealth Effects LLC acquired a new position in shares of SCYNEXIS in the 2nd quarter worth approximately $56,000. BlackRock Inc. bought a new stake in shares of SCYNEXIS in the 2nd quarter valued at $169,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of SCYNEXIS during the fourth quarter worth $1,255,000. Institutional investors own 54.37% of the company’s stock.

SCYNEXIS Company Profile

(Get Free Report)

SCYNEXIS, Inc is a late‐stage biopharmaceutical company focused on developing and commercializing novel anti‐infective therapies. Headquartered in Jersey City, New Jersey, the company’s primary research and development efforts center on combating invasive and chronic fungal infections, an area of high unmet medical need. SCYNEXIS’s scientific platform is built around its proprietary triterpenoid class of antifungals, which are designed to address resistance and safety limitations associated with existing treatments.

The company’s lead product candidate, ibrexafungerp, represents the first oral glucan synthase inhibitor to reach clinical development.